Holen Sie sich die Stockscreener-App
24.54
1.01%
-0.25
Handel nachbörslich:
24.50
-0.04
-0.16%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer CEO is latest to say Trump should get Nobel Peace Prize – for something much of MAGA hates - AOL.com
Cassidy, Pfizer CEO: Trump worthy of Nobel prize for COVID vaccine - AOL.com
Trump "worthy of the Nobel Peace Prize" for COVID vaccines, Pfizer CEO says - Axios
Pfizer, Moderna, Novavax respond to Trump’s criticism of COVID shot success - Seeking Alpha
Pfizer, Moderna defend COVID vaccine effectiveness after Trump remarks - Reuters
Pfizer collaboration with Olema may spark future bidding waranalyst (OLMA:NASDAQ) - Seeking Alpha
Prostate Cancer Pipeline Analysi, 2025 by DelveInsight | Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Phar - Barchart.com
Pfizer defends COVID-19 vaccine effectiveness after Trump remarks - Reuters
Responding to Trump, Pfizer CEO Bourla stands by Covid-19 vaccine data - Endpoints News
Pfizer responds to Trump’s call for Covid-19 vaccine data, says Operation Warp Speed deserves Nobel Peace Prize - news8000.com
Pfizer (PFE) Partners With Olema For New Metastatic Breast Cancer Study - simplywall.st
Pfizer Reaffirms Transparency Commitment On COVID-19 Vaccine Data - Nasdaq
PDE4B Inhibitor Market Poised for Strong Growth by 2034 | DelveInsight - GlobeNewswire Inc.
Pfizer Defends Covid Shot, Says Trump Deserves Nobel Prize - Yahoo Finance
Pfizer defends Covid-19 vaccine transparency in response to Trump - The Edge Malaysia
Pfizer Defends Covid Vaccine Transparency in Response to Trump - Bloomberg.com
Pfizer : Responds to Success of Operation Warp Speed and Reaffirms Transparency of COVID Vaccine Data - MarketScreener
Pfizer says it will soon share new data on latest vaccine strain which FDA approved - MarketScreener
Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.
Pfizer (PFE) Volatility and Risk Allocation: Navigating a Shifting Pharmaceutical Landscape - AInvest
Pfizer's Strategic Reinvention: Execution Discipline and Risk Allocation Reshape Valuation Narrative - AInvest
Pfizer's Strategic Volatility: Tactical Entry Points and Rule-Based Trading in a Biotech Recovery - AInvest
Pfizer's Strategic Volatility: Decoding Recent Share Price Swings and Tactical Entry Points - AInvest
Pfizer's Surging Momentum: A Catalyst for Large-Cap Biotech Growth - AInvest
$33M Pfizer Antitrust Deal OK'd, First MDL Trial Date Set - Law360
Pfizer's Golden Cross and Pipeline Progress: A Dividend-Driven Turnaround or a Value-Trap Mirage? - AInvest
Pfizer's Pipeline Monetization and 7% Yield: A Dual-Engine Opportunity in a Re-Rating Pharma Landscape - AInvest
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Pfizer Defends Transparency On COVID-19 Vaccine Data, Says Trump’s ‘Operation Warp Speed’ Effort Deserves Nobel Peace Prize - Stocktwits
Backtesting results for Pfizer Inc. trading strategiesTrade Risk Report & Safe Entry Trade Signal Reports - Newser
Can Pfizer Inc. recover in the next quarterTrade Signal Summary & Daily Chart Pattern Signal Reports - Newser
Olema stock jumps after new clinical trial collaboration with Pfizer - Investing.com
Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com
Pfizer: Pipeline Monetization Shows Great PromiseRich Yields Pending Re-Rating (NYSE:PFE) - Seeking Alpha
Is Pfizer Stock Underperforming the Nasdaq? - Yahoo Finance
Olema Pharmaceuticals, Pfizer Collaborate for Clinical Trial of Breast Cancer Treatment - MarketScreener
Olema Pharmaceuticals Partners with Pfizer for New Trial - TipRanks
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer - The Manila Times
Pfizer, Moderna in focus as Trump demands answers on COVID success - Seeking Alpha
Olema Oncology Announces New Clinical Trial Agreement with - GlobeNewswire
Novel Breast Cancer Treatment: Olema and Pfizer Join Forces on Promising Drug Combination Study - Stock Titan
Is Pfizer Inc. reversing from oversold territoryJuly 2025 Action & Smart Allocation Stock Tips - Newser
Pfizer (PFE) Valuation in Focus Following FDA Approval of Updated COVID-19 Vaccine - simplywall.st
Stock Analysis | Pfizer OutlookMixed Signals as Technicals Deter and Fundamentals Stay Strong - AInvest
Contract Pharma Talks with Bruno Sciamanna and Lillian Glennon of Pfizer CentreOne - Contract Pharma
Pfizer Inc. (PFE)’s Updated COVID-19 Vaccine COMIRNATY LP.8.1 Gets FDA Approval, Ships Nationwide - Yahoo Finance
Trump Demands Pfizer, Other Covid Drug Makers To… - inkl
Unit Dose Packaging Market Top Companies StudyPfizer Inc., - openPR.com
Is Pfizer Inc. trending in predictive chart modelsWeekly Profit Summary & Real-Time Buy Signal Notifications - Newser
Advanced analytics toolkit walkthrough for Pfizer Inc.Quarterly Market Summary & Expert Approved Momentum Ideas - Newser
How to read the order book for Pfizer Inc.July 2025 Weekly Recap & Weekly High Potential Alerts - Newser
Pfizer's Golden Cross Signals Strength: How to Play the Stock - Yahoo Finance
A Look at Pfizer’s Valuation After FDA Approval of Next-Gen COVID Vaccine for Older Adults and High-Risk Groups - Yahoo Finance
Chart overlay techniques for tracking Pfizer Inc.Weekly Gains Report & Verified Swing Trading Watchlist - Newser
Relative strength of Pfizer Inc. in sector analysisIPO Watch & Long-Term Investment Growth Plans - Newser
Using flow based indicators on Pfizer Inc.Earnings Recap Summary & Reliable Entry Point Trade Alerts - Newser
Pfizer Inc. Rebound Backed by Sentiment Shift getLinesFromResByArray error: size == 0 - thegnnews.com
Should FDA Approval of Updated COVID Vaccine for Vulnerable Groups Prompt a Closer Look at Pfizer (PFE)? - simplywall.st
Pfizer Inc. - Britannica
Pfizer (PFE) Announces FDA Approval of sBLA for Pfizer-BioNTech COVID-19 Vaccine - MSN
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):